Half-year report · Q2
4151.TEDINET S100WFU4
Period2025-01-01 → 2025-06-30
Filed2025-07-31
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 45
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥230.7bn | 2025-01-01 → 2025-06-30 | Cons. | Revenue IFRS |
| Revenue | ¥495.6bn | 2024-01-01 → 2024-12-31 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥233.0bn | 2024-01-01 → 2024-06-30 | Cons. | Revenue IFRS |
| Profit before tax | ¥22.0bn | 2025-01-01 → 2025-06-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥83.5bn | 2024-01-01 → 2024-12-31 | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥46.5bn | 2024-01-01 → 2024-06-30 | Cons. | Profit loss before tax IFRS |
| Net income (owners) | ¥16.3bn | 2025-01-01 → 2025-06-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥59.9bn | 2024-01-01 → 2024-12-31 | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥37.8bn | 2024-01-01 → 2024-06-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income | ¥16.3bn | 2025-01-01 → 2025-06-30 | Cons. | Profit loss IFRS |
| Net income | ¥37.8bn | 2024-01-01 → 2024-06-30 | Cons. | Profit loss IFRS |
| Total assets | ¥1.07T | at 2025-06-30 | Cons. | Assets IFRS |
| Total assets | ¥1.07T | at 2024-12-31 | Cons. | Assets IFRS |
| Total assets | ¥1.07T | at 2024-06-30 | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥224.5bn | at 2025-06-30 | Cons. | Liabilities IFRS |
| Total liabilities | ¥216.6bn | at 2024-12-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥842.0bn | at 2025-06-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥850.8bn | at 2024-12-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥862.7bn | at 2024-06-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥836.4bn | at 2023-12-31v | Cons. | Equity IFRS |
| Equity (owners) | ¥842.0bn | at 2025-06-30 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥850.8bn | at 2024-12-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥862.7bn | at 2024-06-30 | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥234.6bn | at 2025-06-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥244.7bn | at 2024-12-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥311.1bn | at 2024-06-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥403.1bn | at 2023-12-31v | Cons. | Cash and cash equivalents IFRS |
| Operating cash flow | ¥39.8bn | 2025-01-01 → 2025-06-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥67.9bn | 2024-01-01 → 2024-12-31 | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥46.9bn | 2024-01-01 → 2024-06-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Investing cash flow | −¥34.7bn | 2025-01-01 → 2025-06-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥142.4bn | 2024-01-01 → 2024-12-31 | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥80.5bn | 2024-01-01 → 2024-06-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Financing cash flow | −¥17.2bn | 2025-01-01 → 2025-06-30 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥84.7bn | 2024-01-01 → 2024-12-31 | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥63.2bn | 2024-01-01 → 2024-06-30 | Cons. | Net cash provided by used in financing activities IFRS |
| EPS (basic) | ¥31.18 | 2025-01-01 → 2025-06-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥113.06 | 2024-01-01 → 2024-12-31 | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥70.76 | 2024-01-01 → 2024-06-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (diluted) | ¥31.18 | 2025-01-01 → 2025-06-30 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥113.06 | 2024-01-01 → 2024-12-31 | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥70.75 | 2024-01-01 → 2024-06-30 | Cons. | Diluted earnings loss per share IFRS |
| Equity ratio | 78.9% | at 2025-06-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 79.7% | at 2024-12-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 80.6% | at 2024-06-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
All source rows · 665
| Item | Context | Value | Unit |
|---|---|---|---|
| Description of fact that companys business comprises single segment IFRS | CurrentYTDDuration | Original text (Japanese)当社グループは、「医薬事業」の単一セグメントであるため、報告セグメント別の記載は省略しています。 | |
| Notes cash and cash equivalents condensed quarterly consolidated financial statements IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Notes revenue2 condensed quarterly consolidated financial statements IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Notes selling general and administrative expenses condensed quarterly consolidated financial statements IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Notes other income condensed quarterly consolidated financial statements IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Notes other expenses condensed quarterly consolidated financial statements IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Notes earnings per share condensed quarterly consolidated financial statements IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Notes financial instruments condensed quarterly consolidated financial statements IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Notes share capital and other equity items condensed quarterly consolidated financial statements IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Notes dividends condensed quarterly consolidated financial statements IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Notes business combinations condensed quarterly consolidated financial statements IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Notes cash flow information condensed quarterly consolidated financial statements IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Notes subsequent events condensed quarterly consolidated financial statements IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Other information consolidated financial statements etc (text) | CurrentYTDDuration | Text · Plus | |
| Information about company which provides guarantee to reporting company (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |